Metabolite changes in HT-29 xenograft tumors following HIF-1α inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo

NMR in Biomedicine

Volumn 18, Issue 7, 2005, Pages 430-439

  Jordan, Bénédicte F ^a,b   Black, Kvar ^a   Robey, Ian F ^a   Runquist, Matthew ^c   Powis, Garth ^d   Gillies, Robert J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer chemotherapy; H MRS; HIF 1 ; HT 29 tumor xenografts; PX 478

Indexed keywords

BIOASSAY; BIOCHEMISTRY; CELL CULTURE; CHEMOTHERAPY; GRAFTS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; TUMORS;

CANCER CHEMOTHERAPY; METABOLITE CHANGES; TUMOR XENOGRAFTS;

METABOLITES;

2 AMINO 3 [4 N,N BIS(2 CHLOROETHYL)AMINO]PHENYLPROPIONIC ACID; ANTINEOPLASTIC AGENT; CARDIOLIPIN; CHOLINE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PX 478; TUMOR EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL METABOLISM; CELL STRAIN HT29; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; EX VIVO STUDY; FEMALE; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; METABOLITE; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHOLINE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, SCID; MUSTARD COMPOUNDS; NEOPLASM TRANSPLANTATION; PHENYLPROPIONATES; TISSUE EXTRACTS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 27844601569     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.977     Document Type: Article

References (64)

1. Hoeckel M, Schlenger K, Aral B, Mitza M, Schaffer U, Vaupel P. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56: 4509-4515.
2. Moulder J, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metast. Rev. 1987; 5: 313-341.
3. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Micro. Res. Technol. 2002; 59: 41-48.
4. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. 2004; 4: 891-899.
5. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, Asaka M, Katoh H, Sugiyama T, Hosokawa M, Kobayashi M. Dominant-negative hypoxia-inducible factor-1α reduces tumor-igenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 2003; 162: 1283-1291.
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
7. Semenza GL. Hypoxia, clonal selection and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 2000; 35: 71-103.
8. Powis G, Kirkpatrick L. HIF-1α as a cancer drug target. Mol. Cancer Ther. 2004; 3: 647-654.
9. Chilov D, Camneish G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1α (HIF-1α): heterodimerization with ARNT is not necessary for nuclear accumulation of HEF-1α. J. Cell Sci. 1999; 112: 1203-1212.
10. Minchenko A, Salceda S, Bauer T. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell. Mol. Biol. Res. 1994; 40: 35-39.
11. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Am. Phys. Soc. 2000; 88: 1474-1480.
12. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible factor-1α by the ubiquitin-proteosome pathway. J. Biol. Chem. 1999; 274: 6519-6525.
13. Zhong H, De Marco A, Laughner E, Lim M, Hilton D, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Over-expression of hypoxia-inducible factor 1 alpha in common human cancers and metastases. Cancer Res. 1999; 59: 5830-5835.
14. Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, Talks K. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenicmolecular profile of tumors and survival. Br. J. Cancer 2001; 85: 881-890.
15. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor-1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 2001; 7: 1661-1668.
16. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97: 1573-1581.
17. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001; 61: 2911-2916.
18. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Over-expression of hypoxia-inducible factor-1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000; 60: 4693-4696.
19. Zagzag D, Zhong H, Scalzetti J, Laughner E, Simons J, Semenza G. Expression of hypoxia-inducible factor-1 alpha in brain tumors: association with angiogenesis, invasion and progression. Cancer 2000; 88: 2606-2618.
20. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 alpha. Mol. Cancer Ther. 2004; 3: 233-244.
21. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. 2005. Imaging the effects of hif-1 alpha inhibition by Diffusion and Dynamic Contrast Enhanced MRI. Neoplasia 2005; 7: 475-485.
22. 31P measurements of response to treatment. NMR Biomed. 1998; 11: 314-340.
23. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000; 2: 166-189.
24. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res. 2001; 3: 36-40.
25. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, Swartz HM. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000; 2: 152-165.
26. Nurenberg P, Sartoni-D'Ambrosia G, Szczepaniak LS. Magnetic resonance spectroscopy of renal and other retroperitoneal tumors. Curr. Opin. Urol. 2002; 12: 375-380.
27. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64: 4270-4276.
28. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61: 3599-3603.
29. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002; 94: 1197-1203.
30. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59: 80-84.
31. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, Arnold DL. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat. Med. 1996; 2: 323-325.
32. Cheng LL, Chang IW, Smith BL, Gonzalez RG. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J. Magn. Reson. 1998; 135: 194-202.
33. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002; 15: 327-337.
34. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002; 62: 1966-1970.
35. 1H MRSI. J. Magn. Reson. Imaging. 2002; 16: 464-476.
36. 1H MR spectroscopy of brain tumours and masses. NMR Biomed. 2003; 16: 123-131.
37. Fan G, Sun B, Wu Z, Guo Q, Guo Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin. Radiol. 2004; 59: 77-85.
38. Haase A, Frahm J, Hanicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys. Med. Biol. 1985; 30: 341-344.
39. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann. N. Y. Acad. Sci. 1987; 508: 333-348.
40. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn. Reson. Med. 2003; 50: 1134-1143.
41. Morse DL, Gillies RJ. Choline containing compounds as diagnostic, prognostic and therapeutic response indicators for breast cancer. In Recent Advances in MR Imaging and Spectroscopy, Jagannathan NR (ed.). Jaypee Brothers Medical Publishers: New Delhi, 2005; 345-397.
42. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 2001; 84: 1016-1022.
43. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 2004; 233: 424-431.
44. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999; 59: 3112-3118.
45. Beckonert O, Monnerjahn J, Bonk U, Leibfritz D. Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed. 2003; 16: 1-11.
46. Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, Rodriguez-Vallejo JM. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn. Reson. Imaging. 1999; 17: 755-765.
47. Moreno A, Arus C. Quantitative and qualitative characterization of 1H NMR spectra of colon tumors, normal mucosa and their perchloric acid extracts: decreased levels of myo-inositol in tumours can be detected in intact biopsies. NMR Biomed. 1996; 9: 33-45.
48. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
49. Glaholm J, Leach MO, Collins DJ, Mansi J, Sharp JC, Madden A, Smith IE, McCready VR. In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet. 1989; i: 1326-1327.
50. Tausch-Treml R, Baumgart F, Ziessow D, Kopf-Maier P. 31P NMR spectroscopy of a xenografted hypopharynx carcinoma: effects of tumor growth and treatment with cisplatin on the tumor phosphorus metabolism, histology and cytokinetics. NMR Biomed. 1992; 5: 127-136.
51. de Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O. In vivo 31-P MRS of experimental tumours. NMR Biomed. 1993; 6: 345-365.
52. Sijens PE, Eggermont AM, van Dijk PV, Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed. 1995; 8: 215-224.
53. Griffiths JR, Tate AR, Howe FA, Stubbs M. Magnetic resonance spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur. J. Cancer. 2002; 38: 2085-2093.
54. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad. Radiol. 2004; 11: 368-376.
55. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
56. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 2003; 95: 1624-1633.
57. Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998; 11: 354-359.
58. Merchant TE, Kasimos JN, Vroom T, de Bree E, Iwata JL, de Graaf PW, Glonek T. Malignant breast tumor phospholipid profiles using (31)P magnetic resonance. Cancer Lett. 2002; 176: 159-167.
59. Sterin M, Cohen JS, Mardor Y, Berman E, Ringel I. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Cancer Res. 2001; 61: 7536-7543.
60. Lehnhardt FG, Rohn G, Ernestus RI, Grune M, Hoehn M. 1H- and (31)P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components. NMR Biomed. 2001; 14: 307-317.
61. Tarnawski R, Sokol M, Pieniazek P, Maciejewski B, Walecki J, Miszczyk L, Krupska T. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 1271-1276.
62. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60: 916-921.
63. Poptani H, Bansal N, Graham RA, Mancuso A, Nelson DS, Glickson JD. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (Se1MQC) and dynamic contrast enhanced imaging. NMR Biomed. 2003; 16: 102-111.
64. Troy H, Chung Y-L, Madhu B, Mayr M, Ly L, Blouw B, Johnson R, Griffiths JR, Stubbs M. A metabolomic study of wild type and HIF-1α deficient astrocytomas measured by in vivo and in vitro 1H MRS. Proc. ISMRM 2005; 13: 2040.